| Psoriasis
Rasuvo vs Avsola
Side-by-side clinical, coverage, and cost comparison for psoriasis.Deep comparison between: Rasuvo vs Avsola with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAvsola has a higher rate of injection site reactions vs Rasuvo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Avsola but not Rasuvo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rasuvo
Avsola
At A Glance
SC injection
Once weekly
Folate analog metabolic inhibitor
IV infusion
Every 6-8 weeks
TNF-alpha inhibitor
Indications
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Psoriasis
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Psoriasis
Dosing
Rheumatoid Arthritis 7.5 mg SC once weekly as starting dose; adjust gradually to achieve optimal response; doses greater than 20 mg/wk associated with increased serious toxicity; available doses 7.5-30 mg in 2.5 mg increments.
Juvenile polyarthritis 10 mg/m2 SC once weekly as starting dose; adjust gradually to achieve optimal response.
Psoriasis 10-25 mg SC once weekly as starting dose; adjust gradually; do not ordinarily exceed 30 mg/week; reduce to lowest effective dose and longest possible rest period once optimal response achieved.
Crohn Disease, Ulcerative Colitis, Arthritis, Psoriatic, Psoriasis 5 mg/kg IV induction at weeks 0, 2, and 6, followed by 5 mg/kg every 8 weeks maintenance.
Rheumatoid Arthritis 3 mg/kg IV induction at weeks 0, 2, and 6, followed by 3 mg/kg every 8 weeks maintenance, in combination with methotrexate.
Ankylosing Spondylitis 5 mg/kg IV induction at weeks 0, 2, and 6, followed by 5 mg/kg every 6 weeks maintenance.
Contraindications
- Pregnancy
- Alcoholism, alcoholic liver disease, or other chronic liver disease
- Overt or laboratory evidence of immunodeficiency syndromes
- Preexisting blood dyscrasias such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia
- Known hypersensitivity to methotrexate
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab products, any inactive ingredient of AVSOLA, or murine proteins
Adverse Reactions
Most common (>=10%) Elevated liver function tests, nausea, vomiting
Serious Ulcerative stomatitis, leukopenia, hepatotoxicity, bone marrow suppression, interstitial pneumonitis, opportunistic infections, embryo-fetal toxicity, malignant lymphomas
Most common (>10%) Infections (upper respiratory, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain
Serious Pneumonia, cellulitis, abscess, skin ulceration, sepsis, bacterial infection, lymphoma, hepatotoxicity
Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, acute liver failure, anaphylactic shock, cerebrovascular accidents, myocardial ischemia
Pharmacology
Methotrexate is a folate analog metabolic inhibitor that inhibits dihydrofolic acid reductase, interfering with DNA synthesis, repair, and cellular replication; in rheumatoid arthritis the mechanism may involve immune function modulation, and in psoriasis it exploits the differential in epithelial cell proliferation rates.
TNF-alpha inhibitor; chimeric IgG1kappa monoclonal antibody that neutralizes TNFalpha by binding with high affinity to the soluble and transmembrane forms of TNFalpha, inhibiting binding of TNFalpha with its receptors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rasuvo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Avsola
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Rasuvo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Avsola
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Rasuvo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Avsola
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rasuvo.
No savings programs available for Avsola.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RasuvoView full Rasuvo profile
AvsolaView full Avsola profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.